Citigroup
BCAX

Citigroup’s Bicara Therapeutics BCAX Stock Holding History

Citigroup’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49M Buy
50,240
+40,655
+424% +$907K ﹤0.01% 3150
2026
Q1 		$191K Sell
9,585
-57,112
-86% -$983K ﹤0.01% 4028
2025
Q4 		$1.12M Buy
66,697
+66,041
+10,067% +$1.13M ﹤0.01% 3070
2025
Q3 		$10.4K Sell
656
-10,864
-94% -$122K ﹤0.01% 5013
2025
Q2 		$107K Sell
11,520
-5,938
-34% -$70.8K ﹤0.01% 4373
2025
Q1 		$227K Buy
17,458
+1,970
+13% +$26.2K ﹤0.01% 4131
2024
Q4 		$270K Buy
15,488
+15,236
+6,046% +$317K ﹤0.01% 4222
2024
Q3 		$6.42K Buy
+252
New +$6.43K ﹤0.01% 5335

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citigroup's BCAX Position: Q2 2026 in Review

Citigroup increased its Bicara Therapeutics (BCAX) stake by 424% in Q2 2026, buying an estimated $907K and bringing the position to 50,240 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #3150.

Citigroup first reported a position in BCAX in Q3 2024 and has held it in 8 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Citigroup held 50,240 shares of Bicara Therapeutics worth $1.49M as of Q2 2026.
  • Citigroup bought 40,655 Bicara Therapeutics shares in Q2 2026, an estimated $907K.
  • Bicara Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3150 holding.
  • Citigroup first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.